Clinical Trial Update: MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MLN9708 (ixazomib) for prophylaxis of chronic graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation Complications
• Graft-versus-host Disease

Drugs mentioned

• MLN9708 (ixazomib)

Snippet

Sponsor: Mehdi Hamadani | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-08